Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Integrating Acupuncture Within a Wellness Intervention for Women With Multiple Sclerosis: A Feasibility Study.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Multiple sclerosis, vitamin D, and HLA-DRB1*15.
Delayed visual evoked response in optic neuritis.
Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Gene expression in brain during cuprizone-induced demyelination and remyelination.
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent.
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.
Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
TECFIDERA prescribing information
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.
Multiple sclerosis in Hispanics: a study of clinical disease expression.
MS clinical trials: what can subgroup analyses teach us?
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination.

Pages